Get the Stockscreener App
0.698
10.16%
-0.0789
After Hours:
.68
-0.018
-2.58%
Traws Pharma Inc stock is traded at $0.698, with a volume of 331.90K.
It is down -10.16% in the last 24 hours and down -49.05% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
See More
Previous Close:
$0.7769
Open:
$0.78
24h Volume:
331.90K
Relative Volume:
0.15
Market Cap:
$10.63M
Revenue:
$2.73M
Net Income/Loss:
$-19.43M
P/E Ratio:
-0.307
EPS:
-2.2739
Net Cash Flow:
$-17.91M
1W Performance:
-17.23%
1M Performance:
-49.05%
6M Performance:
-47.91%
1Y Performance:
-51.86%
1-Day Range:
$0.665
$0.78
1-Week Range:
$0.665
$0.869
52-Week Range:
$0.64
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
0.698 | 11.83M | 2.73M | -19.43M | -17.91M | -2.2739 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | H.C. Wainwright | Buy |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
Traws Pharma Company Profile & Introduction - Moomoo
Traws Pharma files prospectus for $139.2M mixed shelf offering - scanx.trade
TRAWTraws Pharma Inc Options - Finviz
Traws Pharma (TRAW) renews shelf for $139.2M unsold securities - Stock Titan
Price to book forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Price to sales forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Enterprise value to revenue forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Enterprise value to EBIT forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Traws Pharma, Inc. Actuals & Estimates (NASDAQ:TRAW) - TradingView
TRAW Forecast — Price Target — Prediction for 2027 - TradingView
Traws Pharma, Inc. Actuals & Estimates (FWB:0T20) - TradingView
0T20 Forecast — Price Target — Prediction for 2027 - TradingView
Traws Pharma stock falls as UK regulator delays key flu study - MSN
Traws Pharma Inc. (TRAW) Edges Higher With Modest Gain; Key Resistance at $0.90 in FocusSentiment Extreme - dars.gov.et
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program - Sahm
Traws Pharma Inc (TRAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Traws Pharma updates influenza prophylaxis program guidance - grafa.com
Update on Traws Pharma (TRAW) Toxicology Data Submission - GuruFocus
Traws Pharma to Resubmit Influenza Prophylaxis Data to UK Regulators – Latest Update on Tivoxavir Marboxil Program 12 – Minichart - Minichart
Traws Pharma prepares new toxicology package for influenza drug - TipRanks
Traws Pharma (TRAW) plans Q3 2026 MHRA resubmission for Phase 2a flu study - Stock Titan
Why Did TRAW Stock Slump 28% After Hours? - Stocktwits
Traws Pharma Positions Long-Acting Antivirals for Influenza & Outbreak Threats as Sector Opportunities Expand - Streetwise Reports
Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program - Streetwise Reports
TRAWS PHARMA INC (TRAW) Stock Chart - ChartMill
Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Traws Pharma Inc (TRAW) Institutional Confidence - TradingKey
TRAW Downgraded by HC Wainwright & Co. -- Price Target Adjusted to $1.00 - GuruFocus
H.C. Wainwright Downgrades Traws Pharma(TRAW.US) to Hold Rating, Cuts Target Price to $1 - Moomoo
Traws Pharma Inc (TRAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Traws Pharma Inc (TRAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Traws Pharma Inc (TRAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Traws Pharma Inc (TRAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Traws Pharma Inc (TRAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Traws Pharma Inc (TRAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Traws Pharma (TRAW) Plunges Over 32%: Support Test and Liquidity ConcernsSentiment Extreme - newsline.com
Bandwidth, Traws Pharma and other big stocks moving lower in Monday's pre-market session - MSN
TRAW Downgraded by Ladenburg Thalmann -- Rating Changed to Neutr - GuruFocus
Traws Delays Influenza Study After UK Regulatory Setback - MyChesCo
Traws Pharma shares slide after UK regulator postpones influenza study - MSN
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study - Benzinga
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Micron, Nebius surge premarket; Traws Pharma tumbles By Investing.com - Investing.com India
Micron, Nebius surge premarket; Traws Pharma tumbles - Investing.com
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study - Yahoo Finance
Why is Traws Pharma stock tumbling today? By Investing.com - Investing.com Canada
Traws Pharma stock tumbles after UK regulator delays flu trial By Investing.com - Investing.com Canada
Traws Pharma gains after hantavirus drug development update amid cruise ship outbreak - MSN
Traws Pharma Defers Phase 2a Human Influenza Study After UK MHRA Review, Advances Alternative Antiviral Candidates 1 – Minichart - Minichart
Traws Pharma (TRAW) Delays Phase 2a Trial of Tivoxavir Marboxil - GuruFocus
Traws Pharma Inc Stock (TRAW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):